News
Featured
Last week, the PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings together non-profit, philanthropic, and private sector partners for a common mission to develop novel TB medicines that are better-tolerated, shorter in duration, and simpler to use than existing options. The collaboration includes members such as Evotec, GSK, Janssen, Otsuka, TB...
News
22 Mar 2017
March 21, 2017 Infectex Announces Positive Phase 2b-3 Clinical Trial Results of SQ109 for the Treatment of Multidrug-Resistant Pulmonary Tuberculosis Moscow, Russia and Rockville, MD, USA -- Infectex Ltd., a Russian portfolio company of Maxwell Biotech Venture Fund (MBVF), today announced positive...
10 Mar 2017
WGND Co-chair, Barbara Laughon, and Sequella Inc. CEO, Carol Nacy, co-authored a correspondence to Nature Reviews regarding the October 2016 Article, “Tuberculosis”. “In their recent Primer article (Tuberculosis. Nat. Rev. Dis. Primers 2, 16076 (2016))1, Madhukar Pai and colleagues give an...
1 Mar 2017
28 FEBRUARY 2017 | GENEVA - WHO reaffirms the critical need for research and development (R&D) of new antibiotics to tackle the threat of drug-resistant tuberculosis (TB). "Addressing drug-resistant TB research is a top priority for WHO and for the world," said Dr Margaret Chan, WHO Director-...
17 Feb 2016
Tuberculosis continues to become more resistant to existing drug regimens resulting in a need for constant innovation on the part of drug researchers. In an article published by Medicalxpress.com which can be found here , researchers are reported to have found a chemical alteration that makes...
22 Nov 2015
20 November 2015 – Geneva, Switzerland — The world is losing its battle with tuberculosis (TB), which is now the biggest infectious killer globally, causing 1.5 million deaths every year. Without a clear investment plan and a complete overhaul in how this disease is tackled, TB is unlikely to be...
22 Nov 2015
Cape Town, South Africa, Dec. 5, 17:30 – 20:30 We invite you to join us for the Stop TB Partnership Working Group on New Drugs’ Annual Meeting 2015 at Southern Sun Cape Sun Hotel , Cape Town, South Africa, on Saturday, Dec. 5th from 17:30 to 20:30. This meeting is held before the 46th Union World...
11 Jun 2015
10 June 2015 – Geneva, Switzerland – The Stop TB Partnership is today launching the online consultation into the first public draft of the Global Plan to Stop TB 2016-2020. The consultation process is open to everyone to share information, ideas and experiences, and, will run from 10 June to 10...
31 May 2015
Tuberculosis Drug Development: Towards a Critical Path for Developing New Regimes to Treat Tuberculosis Volume 211 suppl 3 June 15, 2015 Click here for access to supplement Articles: Eric Nuermberger and Debra Hanna Assessing the Landscape of Tools and Approaches for Novel Tuberculosis Regimen...
19 Feb 2015
TB Alliance announced that its compound TBA-354 has started Phase I clinical trials. This announcement is particularly exciting given that TBA-354 is the first TB drug to enter Phase I trials since 2009. TBA-354 is a next generation compound in the nitroimidazole class, which also includes...
7 Jan 2015
Researchers at the Center for Tuberculosis Research located at Johns Hopkins University School of Medicine have shown that heart medication, verapamil administered in combination with bedaquline lowers the toxicity of the TB drug without altering its efficacy. The paper, titled ‘ Verapamil...
23 Oct 2014
22 OCTOBER 2014 AT 12:01 a.m. EDT CONTACT Mike Frick, Treatment Action Group +1 405.388.4490 New York, NEW YORK, OCTOBER 22, 2014 —Worldwide, governments, foundations, and companies invested US$676.7 million in research to develop new drugs, vaccines, and diagnostics against tuberculosis (TB) in...
21 Sep 2014
We invite you to join us for the Stop TB Partnership Working Group on New Drugs’ Annual Meeting 2014 at AC Hotel Barcelona Forum , Barcelona, Spain, on Wednesday, Oct. 29th from 15:00 to 19:00. This meeting is held before the 45th Union World Conference on Lung Health (The Union). During the...
8 Sep 2014
Moxifloxacin Results of the Phase III REMoxTB clinical trial were published in the New England Journal of Medicine on September 7th, 2014. REMox or Rapid Evaluation of Moxifloxacin in Tuberculosis (REMoxTB) was a trial designed to determine whether replacement of either ethambutol or isoniazid with...
20 Jul 2014
Scientists at Janssen Pharmaceutica have characterized a novel resistance mechanism to Bedaquiline (BDQ), a second line antibiotic for the treatment of MDR-TB. The research study , published in Plos One , showed that tuberculosis resisted BDQ treatment by developing a mechanism to pump the drug out...
14 Jul 2014
A new study published by Dr. Kyu Rhee ’s laboratory at the Weill Cornell Medical College details a potential mechanism driving Mycobacterium tuberculosis’ intrinsic resistance to antibiotics. Physicians and scientists have known for many years that tuberculosis is intrinsically resistant to...